|

Scenic’s Chief Scientific Officer Sebastian Nijman explains why genetic modifiers are an untapped source of drug targets

1. scenic biotech genetic modifier image 1

Harnessing genetic modifiers holds great potential to address the present drug target vacuum. Why should every drug developer care about them? Read more